Schizophrenia Research
Volume 115, Issue 2 , Pages 121-129 , December 2009

Symptomatic and functional outcome in youth at ultra-high risk for psychosis: A longitudinal study

Received 7 July 2009 ,Revised 6 September 2009 ,Accepted 7 September 2009.

References 

  1. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, et al. North American prodrome longitudinal study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 2007;33:665–672
  2. Barrowclough C, Tarrier N. Families of Schizophrenic Patients: Cognitive Behavioural Intervention. London: Chapman & Hall; 1992;
  3. Borgwardt SJ, McGuire PK, Aston J, Gschwandtner U, Pflüger MO, Stieglitz RD, et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr. Res. 2008;106:108–114
  4. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, et al. Outreach and support in South London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur. Psychiatr. 2005;20:372–378
  5. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry. 2008;65:28–37
  6. Chen C, Murray RM. How does drug abuse interact with familial and developmental factors in the etiology of schizophrenia?. In:  Keshavan M,  Kennedy J,  Murray R editor. Neurodevelopment and schizophrenia. Cambridge: Cambridge University Press; 2004;p. 248–269
  7. Cornblatt B, Lencz T, Smith S, Auther A. Treatment of schizophrenia prodrome. In:  Stone WS,  Faraone SV,  Tsuang MT editor. Early Clinical Intervention and Prevention in Schizophrenia. Totowa, New Jersey: Humana Press; 2004;p. 303–323
  8. French P, Morrison AP. Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis: A Treatment Approach. Chichester: Wiley; 2004;
  9. Hall R. Global Assessment of Functioning: a modified scale. Psychosomatics. 1995;36:267–275
  10. Haroun N, Dunn L, Haroun D, Cadenhead KS. Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research. Schizophr. Bull. 2006;32:166–178
  11. Harris MG, Burgess PM, Chant DC, Pirkis JE, McGorry PD. Impact of specialized early psychosis treatment programme on suicide: retrospective cohort study. Early Interv. Psychiatry. 2008;2:11–21
  12. Lemos S, Vallina O, Fernández P, Ortega JA, Garcia P, Gutiérrez A, et al. Predictive validity of the Scale of Prodromal Symptoms (SOPS). Actas Esp. Psiquiatr. 2006;34:216–223
  13. McGlashan TH, Miller TJ, Woods SW, Hoffman RE, Davidson L. Instrument for the assessment of prodromal symptoms and states. In:  Miller TJ,  Mednick SA,  McGlashan TH,  Libiger J,  Johannessen JO editor. Early Intervention in Psychotic Disorders. Dordrecht: Kluwer Academic; 2001;p. 135–149
  14. McGlashan TH, Miller TJ, Woods SW, Rosen JL, Hoffman RE, Davidson L. Structured Interview for Prodromal Syndromes. New Haven, Conneticut: PRIME Research Clinic. Yale School of Medicine; 2001;
  15. McGlashan TH, Addington J, Cannon T, Heinimaa M, McGorry P, O'Brien M, et al. Recruitment and treatment practices for help-seeking “prodromal” patients. Schizophr. Bull. 2007;33:715–726
  16. McGorry PD, Yung A, Phillips L, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry. 2002;59:921–928
  17. McGorry PD, Yung AR, Bechdolf A, Amminger P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch. Gen. Psychiatry. 2008;65:25–27
  18. Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, Corcoran CM, et al. Symptom assessment in schizophrenic prodromal states. Psychiatr. Q. 1999;70:273–287
  19. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull. 2007;33:682–687
  20. Navari, S., Dazzan, P., in press. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. doi:10.1017/S0033291709005315.
  21. Nelson B, Yung AR. When things are not as they seem: detecting first-episode psychosis upon referral to ultra high risk (‘prodromal’) clinics. Early Interv. Psychiatry. 2007;1:208–212
  22. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial: a randomized clinical trial of integrated treatment and standard treatment. Schizophr. Res. 2006;83:29–40
  23. Pantelis C, Yücel M, Wood SJ, McGorry PD, Velakoulis D. Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust. N. Z. J. Psychiatry. 2003;37:399–406
  24. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr. Res. 2007;96:25–33
  25. Power P, McGorry PD. First episode psychosis inpatient services: a comparison of the EPPIC and LEO inpatient units. Early Interv. Psychiatry. 2008;2(Suppl. 1):A14
  26. SAS Institute . The MIXED Procedure, SAS/STAT User's Guide, SAS On-line Documentation. Cary, North Carolina: SAS Institute Inc.; 2007;
  27. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, et al. The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia? — a systematic review. Curr. Pharm. Des. 2009;15:2535–2549
  28. Vallejo G, Arnau J, Ato M. Comparative robustness of recent methods for analyzing multivariate repeated measures designs. Educ. Psychol. Meas. 2007;67:410–432
  29. Velthorst E, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, Klaassen R, et al. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr. Res. 2009;109:60–65
  30. Willhite RK, Niendam TA, Bearden CE, Zinberg J, O'Brien MP, Cannon TD. Gender differences in symptoms, functioning and social support in patients at ultra-high risk for developing a psychotic disorder. Schizophr. Res. 2008;104:327-245
  31. Yung AR, McGorry PD, McFarlane CA. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 1996;22:283–303
  32. Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, et al. Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br. J. Psychiatry. 1998;172(Suppl. 33):14–20
  33. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004;67:131–142
  34. Yung AR, Stanford C, Cosgrave E, Killackey E, Phillips L, Nelson B, et al. Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in clinical sample of young people. Schizophr. Res. 2006;84:57–66
  35. Yung AR, Yuen HP, Berger G, Francey S, Hung T, Nelson B, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophr. Bull. 2007;33:673–681

PII: S0920-9964(09)00430-7

doi: 10.1016/j.schres.2009.09.011

Schizophrenia Research
Volume 115, Issue 2 , Pages 121-129 , December 2009

Article Tools

* Image Usage & Resolution